Group 1 - The core viewpoint of the article indicates that Yifan Pharmaceutical acknowledges the need for a product introduction period for its Yilishu product in the U.S. market [2] - The company's business performance in the first three quarters has been negatively impacted by a significant year-on-year decline in revenue from certain cold-related, centralized procurement pharmaceutical products, and vitamin businesses [2]

Core Viewpoint - Yifan Pharmaceutical (002019) is currently in the clinical strategy validation phase for the ACLF indication of F-652, with no clear plans available at this time [1] Group 1 - Yifan Pharmaceutical responded to investor inquiries on an interactive platform regarding the status of F-652 [1] - The ACLF indication for F-652 is still under clinical strategy validation [1] - There are currently no definitive plans for the development of F-652 in the ACLF indication [1]

Group 1 - The core viewpoint of the article is that Yifan Pharmaceutical has provided updates on its clinical projects, specifically F-652, indicating that the clinical approval for indications ACLF and AH was obtained after 2021 [2] Group 2 - The company responded to investor inquiries on its interactive platform regarding the status of its research projects [2]

Core Viewpoint - Yifan Pharmaceutical's product, Compound Yinhua Jiedu Granules, is indicated for dispelling wind and resolving the exterior, as well as clearing heat and detoxifying, based on the treatment plan recommended by the National Health Commission for COVID-19 [2] Group 1 - The formulation of Compound Yinhua Jiedu Granules is derived from the "Yinqiao San," which is included in the COVID-19 treatment guidelines [2] - In 2003, the product was recommended by the Anhui Provincial Drug Administration as a "SARS prevention drug" [2] - Research conducted by China Pharmaceutical University in 2019 demonstrated that Compound Yinhua Jiedu Granules has significant inhibitory and lethal effects on various viruses, including influenza viruses, parainfluenza viruses, and respiratory syncytial viruses [2]

Core Viewpoint - The pharmaceutical industry is shifting focus from speed to quality in drug development and innovation over the next three to five years, emphasizing the importance of data quality, evidence quality, and real-world quality [2] Group 1 - The past emphasis of companies was on speed in drug development and innovation [2] - Many companies have achieved global firsts in innovative drug development recently [2] - Future requirements in the industry will increasingly prioritize quality over speed [2]

Core Viewpoint - Yifan Pharmaceutical (002019) has seen its stock price decline by 1.74% to 12.39 yuan as of December 9, 2025, with a total market capitalization of 15.071 billion yuan. The company announced that some of its products have been included in the National Medical Insurance Catalog for 2025, which is expected to enhance market expansion and sales, although it will not have a significant impact on the company's performance in the short term [1]. Group 1 - As of December 9, 2025, Yifan Pharmaceutical's stock closed at 12.39 yuan, down 1.74% from the previous trading day, with a total market value of 15.071 billion yuan [1]. - The stock opened at 12.69 yuan, reached a high of 12.87 yuan, and a low of 12.38 yuan, with a trading volume of 1.69 billion yuan and a turnover rate of 1.59% [1]. - The National Healthcare Security Administration released the 2025 National Basic Medical Insurance Drug Catalog on December 7, 2025, which includes some of the company's products [1]. Group 2 - The products included in the catalog are the Aibegstine α injection (Yilishu) and the cross-linked sodium hyaluronate injection (Yinikon), which are renewals, and the compound Huangdai tablet (Baixuekang), which has been adjusted to the regular national medical insurance catalog [1]. - The inclusion of these products is expected to facilitate market development and increase sales, but it will not significantly impact the company's performance in the short term [1]. - The catalog will be implemented starting January 1, 2026, with specific medical insurance payment standards to be announced officially [1].

Group 1 - The company announced that some of its products have been included in the 2025 National Medical Insurance Directory, which is expected to enhance market expansion and product sales [1][2] - The innovative drug Aibegersitin α injection and the imported product Dihyaluronic Acid Sodium Injection have been renewed for inclusion, while the compound Huangdai Tablets have been adjusted to the regular national medical insurance directory [1] - The 2025 National Medical Insurance Directory will be officially implemented on January 1, 2026, with specific reimbursement standards and details to be announced by relevant government departments [2] Group 2 - The company’s subsidiary Hefei Xinzhu Biotechnology has received approval for clinical trials of the innovative macromolecule drug N-3C01 injection, targeting advanced solid tumors and non-muscle invasive bladder cancer [4][5] - N-3C01 is a recombinant IL-15/IL-15Rα fusion protein designed to activate immune cells for tumor destruction, showing promising preclinical results in activating NK cells and CD8+ T cells [6] - The approval for clinical trials indicates that the drug meets the necessary requirements for drug registration, although further steps are needed before it can be marketed [5][6]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that certain self-owned or imported products from its wholly-owned or controlled subsidiaries have been included in the "National Medical Insurance Catalog (2025)" published by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025 [1] Group 1 - The innovative drug Aibegesitin α injection (Yilishu®) has been renewed for inclusion in the National Medical Insurance Catalog [1] - The imported general agent product Dihyaluronic Acid Sodium Injection (Yinikon®) has also been renewed for inclusion [1] - The compound Huangdai tablets (Baisuekang®) have been adjusted to the regular National Medical Insurance Catalog [1]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has received approval from the National Medical Products Administration for clinical trials of its innovative macromolecule drug N-3C01 injection, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer (NMIBC) [1] Group 1: Drug Development - The drug N-3C01 is a recombinant IL-15/IL-15Rα fusion protein developed using DNA recombinant technology [1] - N-3C01 activates NK cells and CD8+ T cells, enhancing their anti-tumor efficacy, as demonstrated in preclinical studies [1] - The drug has shown a dose-dependent ability to inhibit tumor growth in mouse models [1] Group 2: Safety and Efficacy - N-3C01 has demonstrated good safety profiles in short-term and long-term safety trials conducted on rats and monkeys [1] - The mechanism of action involves simulating the binding of IL-15 to immune effector cell receptors, thereby activating immune responses against tumors [1]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Hefei Xinzhu Biotechnology Co., Ltd. received approval from the National Medical Products Administration for clinical trials of the innovative macromolecule drug N-3C01 injection, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer (NMIBC) [1] Group 1: Drug Development - N-3C01 is a recombinant IL-15/IL-15Rα fusion protein produced using DNA recombinant technology [1] - The drug activates NK cells and cytotoxic T cells, enhancing their anti-tumor efficacy through the binding of IL-15 with immune effector cell receptors [1] - Preclinical studies indicate that N-3C01 can activate human NK cells and CD8+ T cells in vitro, and it shows a dose-dependent tumor growth inhibition in mouse models [1] Group 2: Safety and Efficacy - N-3C01 demonstrated good safety profiles in short-term and long-term safety trials conducted on rats and monkeys [1]